Daye's Series A funding round secures future of medical innovation for gynaecological health

We have advised health and wellness start-up Daye, focused on bridging the gender gap in medical research and innovation, on its Series A funding round.

Daye, founded in 2017 by Valentina Milanova, is leading the way in transforming an area of medical research that has been chronically underfunded and ignored for decades, shifting the balance towards people having more control over their reproductive health. The start-up launched its inaugural product, a CBD-infused tampon to ease cramping, in 2019.

The investment round means the next stage of its mission to revolutionise gynaecological healthcare can begin, starting with the release of its new microbiome screening tampon; the company also plans to expand into the US market, having enjoyed success in Europe. Daye is also welcoming new investors Hambro Perks, Cross-Border Impact Ventures and MassMutual Ventures.

We have a longstanding relationship with Daye, having advised the company since its seed round in 2019.

Deepti Patankar, associate at Taylor Wessing said: "Daye have some immensely exciting plans for the future and it was great to work with the team on securing this latest funding to achieve their ambitions. Our expertise in advising high-growth start-ups meant we were uniquely placed to help the Daye team with its mission to transform gynaecological health. We wish them well on this new phase for the company."

Valentina Milanova, founder of Daye, said: "We're so excited to have reached this milestone in Daye's history, including bringing on new investors, launching a game-changing new product and laying the groundwork for our international expansion. Josef, Deepti and the wider team have supported us from the very beginning of our journey and Taylor Wessing's world-class advice and support has once again been instrumental in getting this latest investment round over the line."

The deal was led by partner Josef Fuss and associates Deepti Patankar and Nell Cooper in the corporate technology and life sciences team, with support from partner Liz Wilson in the tax and incentives team.